IRVINE, CA, July 26, 2021 (GLOBE NEWSWIRE) — Odyssey Group International, Inc. (OTCQB: ODYY) (“ODYY” or “the Company”), Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on… […]
Bayer has plucked its new head of research and early development from Roche’s pRED organization, where he was doing much the same thing before making the leap. The German pharma company announced this morning that it had signed up Dominik Ruettinger fo… […]
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology and Athyrium Capital have entered into an agreement for the issuance of up to $125 million of notes in two tranches. […]
SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)– #ASCRS2021–Allegro Ophthalmics announces positive results of ex-U.S. Phase 2 trial of ALG-1007 for the treatment of dry eye disease; FDA acceptance of IND. […]
LOS ANGELES: LOS ANGELES, July 23, 2021 /PRNewswire/ — Immix Biopharma, Inc. today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to … […]
Back in May, the FDA revised and expanded a 2019 draft guidance that spells out how to adjust for covariates in the statistical analysis of randomized controlled trials. Building on the ICH’s E9 guideline on the statistical principles for clinical tria… […]
LOS ANGELES: LOS ANGELES, July 23, 2021 /PRNewswire/ — ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals (RPT), today announced the si… […]
SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial res… […]
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology will host a conference call at 1:30 p.m. PT on Aug. 5 following the release of its second quarter 2021 financial results. […]
THOUSAND OAKS, Calif.: THOUSAND OAKS, Calif., July 22, 2021 /PRNewswire/ — Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitati… […]
Copyright © 2021 | MH Magazine WordPress Theme by MH Themes
